Browse Articles

NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine Eric J. Rubin, Oladapo O. Yeku, Stephen Morrissey Jan 02, 2025 DOI: 10.1056/nejme2411485

Long-Acting HIV Medicines and the Pandemic Inequality Cycle — Rethinking Access

New England Journal of Medicine Winnie Byanyima, Linda-Gail Bekker, Matthew M. Kavanagh Jan 02, 2025 DOI: 10.1056/nejmms2412286

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

New England Journal of Medicine Jan 02, 2025 DOI: 10.1056/nejmc2414269

When Blurry Vision Clouds the Bigger Picture

New England Journal of Medicine Rohan Khazanchi, Patricia A. Stoeck, Ryan Gise et al. Jan 02, 2025 DOI: 10.1056/nejmcps2402327

Chronic Myeloid Leukemia with Hyperleukocytosis

New England Journal of Medicine Bashir A. Bashir Jan 02, 2025 DOI: 10.1056/nejmicm2402918

NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

New England Journal of Medicine Eric J. Rubin, Oladapo O. Yeku, Stephen Morrissey Jan 02, 2025 DOI: 10.1056/nejme2411489

NEJM at ESC — Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

New England Journal of Medicine Eric J. Rubin, Jane Leopold, Stephen Morrissey Jan 02, 2025 DOI: 10.1056/nejme2410890

Miles to Go and Nowhere to Sleep

New England Journal of Medicine Heather Kovich Jan 02, 2025 DOI: 10.1056/nejmp2405627

Congenital Spinal Meningocele

New England Journal of Medicine Tariq Parker, Kristopher T. Kahle Jan 02, 2025 DOI: 10.1056/nejmicm2410556

Westermark’s Sign and Palla’s Sign in Pulmonary Embolism

New England Journal of Medicine Yuichiro Shimoyama, Yoshitaka Tomoda Jan 02, 2025 DOI: 10.1056/nejmicm2409241

When Diversity Goals Meet Multiregional Trials

New England Journal of Medicine Gautam U. Mehta, Richard Pazdur, Namandjé N. Bumpus et al. Jan 02, 2025 DOI: 10.1056/nejmp2409392

NEJM at ESC — Asundexian versus Apixaban in Patients with Atrial Fibrillation

New England Journal of Medicine Eric J. Rubin, Jane Leopold, Stephen Morrissey Jan 02, 2025 DOI: 10.1056/nejme2410902

Transitional Justice — A Politico-Legal Approach to Health Equity

New England Journal of Medicine Emily McNeill, Hetty Cunningham, Maya Sabatello Jan 02, 2025 DOI: 10.1056/nejmms2408222

Showing tau the exit

Nature Reviews Drug Discovery M. Teresa Villanueva Jan 01, 2025 DOI: 10.1038/d41573-024-00200-6

Covalent inhibitor engages oncogenic AKT kinase

Nature Reviews Drug Discovery Alex Eccleston Jan 01, 2025 DOI: 10.1038/d41573-024-00197-y

FDA approves first menin inhibitor, for acute leukaemia

Nature Reviews Drug Discovery Asher Mullard Jan 01, 2025 DOI: 10.1038/d41573-024-00198-x

Multi-TACs target solid tumours

Nature Reviews Drug Discovery Sarah Crunkhorn Jan 01, 2025 DOI: 10.1038/d41573-024-00193-2

ENGases to treat IgG-mediated diseases

Nature Reviews Drug Discovery Sarah Crunkhorn Jan 01, 2025 DOI: 10.1038/d41573-024-00190-5

Author Correction: Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets

Nature Reviews Drug Discovery Lieselotte Vande Walle, Mohamed Lamkanfi Jan 01, 2025 DOI: 10.1038/s41573-024-01104-1

Expanding the ligandable proteome

Nature Reviews Drug Discovery Sarah Crunkhorn Jan 01, 2025 DOI: 10.1038/d41573-024-00192-3